LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus
NCT ID: NCT07246005
Last Updated: 2025-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2025-12-01
2027-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement.
* To identify the optimal length of anticoagulation in the treatment of LV Thrombus
After randomisation participants will:
* Continue their prescribed oral anticoagulant for the remainder of the trial
* Discontinue their prescribed oral anticoagulant for the remainder of the trial
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation
NCT03792152
Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants
NCT00438230
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
NCT01619007
Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy
NCT02210819
3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
NCT00365950
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Continue pre prescribed rivaroxaban or apixaban or warfarin
If randomised to this arm, participants will continue on their rivaroxaban or apixaban or warfarin for the study related time period.
Continue rivaroxaban or apixaban or warfarin
The study is asessing the impact of discontinuation of oral anticoagulation in patients with LV thrombus diagnosis.
Discontinue pre prescribed rivaroxaban or apixaban or warfarin
If randomised to this arm, patients (who have already been on OAC for a period of 3 months) will discontinue their rivaroxaban or apixaban or warfarin.
Discontinue rivaroxaban or apixaban or warfarin
discontinue rivaroxaban or apixaban or warfarin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Continue rivaroxaban or apixaban or warfarin
The study is asessing the impact of discontinuation of oral anticoagulation in patients with LV thrombus diagnosis.
Discontinue rivaroxaban or apixaban or warfarin
discontinue rivaroxaban or apixaban or warfarin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* On Apixaban at the time of randomisation
* Completed at least 3 months of anticoagulation treatment for LV thrombus
* Persistent laminar/ mural thrombus or persistent LV dysfunction
Exclusion Criteria
* SSE since LV thrombus diagnosis
* Contraindication to continuing anticoagulation therapy
* Non-ischaemic Cardiomyopathy
* Age less than 18 years
* Unable to consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Queen Mary University of London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Bartholomews Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
G-002409
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
1008221
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.